Comparison of Efficacy of ESWL and Laser Lithotripsy in Chronic Pancreatitis With ERCP
Study Details
Study Description
Brief Summary
This study will compare the efficacy of ESWL and laser lithotripsy in the treatment of pancreatic duct stones with ERCP.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Chronic pancreatitis (CP) is an inflammatory disease that can causes progressive fibrosis of pancreatic tissue and eventually leads to damage of pancreatic exocrine and endocrine. According to statistics, the prevalence of CP in China is 13/10 million, which is still increasing. Pancreatic duct stones are the most important pathological changes of CP. More than 50% of patients with CP are accompanied by pancreatic duct stones, which can lead to pancreatic duct obstruction, hypertension and tissue ischemia. Removal of pancreatic duct stones under Endoscopic Retrograde Cholangiopancreatography (ERCP) are the first choice. ERCP is effective in the treatment of pancreatic duct stones by using basket and/or balloon catheter. But in most cases, ERCP is only suitable for the treatment of pancreatic duct stones (diameter < 5mm) located in the head/body of the Main Pancreatic Duct (MPD). MPD stones larger than 5mm generally require Extracorporeal Shock Wave Lithotripsy (ESWL) or Endoscopic Intraductal Lithotripsy (EIL) for pretreatment. EIL includes Electrohydraulic Lithotripsy (EHL) and Laser Lithotripsy (LL).
ESWL first locates the stone by X-ray, and then uses an electromagnetic pulse generator to direct a higher-energy shock wave to the stone, so that the stone is crushed by thousands of shock waves. The principle of laser lithotripsy is to make the stone absorb strong infrared rays and generate shock waves to achieve the purpose of fragmenting the stone.
In view of the fact that there is no relevant research comparing the overall efficacy of ESWL combined with ERCP and EIL combined with ERCP, it is necessary to evaluate the differences in the therapeutic effects and complications of the two for MPD stones. This research helps to provide evidence-based medical evidence, guide physicians' clinical practice, improve the quality of patients' lives, and reduce the economic burden of patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: ESWL and ERCP The patients will receive intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). The time scale between the last ESWL session and following ERCP will be greater than 48h. ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary. |
Procedure: ESWL and ERCP
First, ESWL will be used for lithotripsy, and then ERCP will be performed to clear the stones after lithotripsy.
|
| Active Comparator: LL and ERCP ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, laser lithotripsy will be performed. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary. |
Procedure: LL and ERCP
After establishing the working channel under ERCP, the stone will be crushed with a laser lithotripter, and then ERCP will clear the stones after lithotripsy.
|
Outcome Measures
Primary Outcome Measures
- technical success rates [during ERCP procedure]
Technical success rates refer to the successful completion of standard procedures or the occurrence of complete spontaneous stone removal.
- clearance rates of pancreatic duct stones [during ERCP procedure]
Clearance rates have been defined as complete, partial, or failure if the proportion of stones cleared was > 90%, 50% - 90%, or < 50%, respectively.
Secondary Outcome Measures
- time taken to completely clear the stone [during ESWL and ERCP procedure]
The time taken to completely clear the stones.
- postoperative complications [30 days after ERCP procedure]
Major post-ERCP complications includes post-ERCP pancreatitis, bleeding, infection, and perforation, which are classified as mild, moderate, or severe, depending mainly on the length of hospitalization and the need for invasive treatment.
- success rates of pancreatic duct decompression [during ERCP procedure]
Successful removal of pancreatic duct obstruction factors by clearing stones and/or placing pancreatic duct stents/nasopancreatic catheters.
Other Outcome Measures
- abdominal pain relief rate [30 days after ERCP procedure]
Postoperative and preoperative abdominal pain was assessed using the Visual Analogue Scale (VAS). VAS can be calculated ranging from 0 (no pain) to 100 (severe pain).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
symptomatic adult patients diagnosed with chronic pancreatitis and pancreatic duct stones;
-
at least one stone (>5 mm in diameter) located in the main pancreatic duct of the head/body of the pancreas;
-
dilation of the proximal main pancreatic duct.
Exclusion Criteria:
-
history of ERCP or ESWL treatment;
-
suspected to have malignant tumors;
-
history of pancreatic surgery or gastrojejunostomy (Billroth II);
-
pancreatic pseudocyst with a diameter >4cm;
-
bile duct stricture secondary to cholangitis or chronic pancreatitis;
-
acute pancreatitis exacerbation or acute exacerbation of chronic pancreatitis (including biliary pancreatitis);
-
coagulation dysfunction (INR≥1.5 or platelet count≤50×10^9/L);
-
pregnant or breastfeeding women;
-
patients who refused to participate in the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Changhai Hospital | Shanghai | China | 200433 |
Sponsors and Collaborators
- Changhai Hospital
Investigators
- Principal Investigator: Liang-hao Hu, MD, Changhai Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
- ECLIPSE20220312